High Nuclear Expression of HDGF Correlates with Disease Progression and Poor Prognosis in Human Endometrial Carcinoma

Table 2

Summary of univariate and multivariate Cox regression analysis of overall survival duration.

Parameter	Univariate analysis			Multivariate analysis
	𝑃	HR	95% CI	𝑃	HR	95% CI
Age
<50 versus ≧50	0.093	0.401	0.138–1.165
Family history of tumor
Negative versus positive	0.279	0.325	0.043–2.487
Education
<Graduation versus ≧graduation	0.298	26.921	0.055–13271.753
Health Insurance
No versus yes	0.089	0.020	0.000–1.811
Career
≦Worker versus >worker	0.272	27.978	0.073–10713.674
Menopausal status
Premenopausal versus postmenopausal	0.559	0.721	0.240–2.160
Complications
With versus without	0.125	0.309	0.069–1.384
FIGO stage
I + II versus III	0.002	5.652	1.892–16.883	0.729	1.392	0.215–9.006
Histological grading
G1 versus G2 versus G3	0.001	4.514	1.896–10.745	0.097	2.170	0.870–5.412
Lymph node status
Negative versus positive	≤0.001	12.232	4.196–35.659	0.070	5.543	0.872–35.231
Depth of myometrial invasion
<50% versus ≧50%	≤0.001	9.745	2.713–34.999	0.090	3.673	0.818–16.498
HDGF expression
Low expression versus high expression	0.004	4.951	1.686–14.544	0.111	2.828	0.787–10.165
Postoperative irradiation
Yes versus no	0.512	1.652	0.368–7.409
Postoperative chemotherapy
Yes versus no	0.175	2.081	0.721–6.005
Postoperative hormone therapy
Yes versus no	0.044	0.267	0.074–0.963	0.703	0.748	0.169–3.322